短肠综合征患者治疗新选择！注射用替度格鲁肽纳入商保创新药目录

Core Viewpoint - The inclusion of injectable Teduglutide in the Commercial Health Insurance Innovation Drug Directory marks a significant advancement in the treatment of short bowel syndrome for adults and children aged one and above, aiming to improve patient access and reduce economic burdens [1][2]. Group 1: Drug Inclusion and Impact - Injectable Teduglutide has been included in the Commercial Health Insurance Innovation Drug Directory, which focuses on high-innovation, clinically valuable drugs that exceed basic medical insurance coverage [1]. - This drug is the first GLP-2 analog approved for short bowel syndrome in China, addressing a long-standing gap in intestinal rehabilitation treatment [3]. - The inclusion is expected to enhance the quality of life for patients suffering from short bowel syndrome, transitioning them from a lack of effective medication to having accessible treatment options [2][3]. Group 2: Patient Demographics and Challenges - Short bowel syndrome is characterized by significantly reduced intestinal absorption area due to extensive small intestine resection, with adult patients often having less than 2 meters of functional intestine [2]. - The prevalence of short bowel syndrome in adults in China is approximately 0.73 per million, with a rising trend observed [2]. - Patients face severe challenges, including reliance on parenteral nutrition (PN) and associated life-threatening complications, which impose heavy financial burdens on families and the healthcare system [3]. Group 3: Policy Support and Accessibility - Drugs included in the Commercial Health Insurance Innovation Drug Directory benefit from the "three exclusions" policy, which provides a more favorable environment for clinical application [4]. - Patients with short bowel syndrome and other high-risk groups can easily enroll in local "Hui Min Bao" insurance programs by the end of December, with coverage effective from January 1 of the following year [4].